Navigation Links
OncoGenex Pharmaceuticals to Webcast Financial Results for Fourth Quarter and Fiscal Year 2008 and Provide Outlook for 2009
Date:3/4/2009

BOTHELL, WA and VANCOUVER, March 4 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that the Company's fourth quarter and fiscal year 2008 financial results will be released on Wednesday, March 11, 2009, and that the Company will host a conference call and live webcast at 4:30 p.m. EDT that afternoon. Management will discuss the company's financial results and provide a 2009 corporate outlook.

A live webcast and slide presentation will be available through the Events and Presentations Web page found in the Investors Relations section of the OncoGenex Web site at http://ir.oncogenex.com. Alternatively, you may access the live conference call by dialing 877-874-1569 (U.S. & Canada) or 719-325-4767 (International). A webcast replay will be available approximately two hours after the call and will be archived at the same Web location for 90 days.

About OncoGenex Pharmaceuticals

OncoGenex Pharmaceuticals is a biopharmaceutical company committed to the development and commercialization of new therapies that address unmet needs in the treatment of cancer. OncoGenex has a deep oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OGX-011, the lead candidate currently completing five Phase 2 clinical studies in prostate, lung and breast cancers, is designed to inhibit the production of a specific protein associated with treatment resistance; OGX-427 is in Phase 1 clinical development; SN2310 has completed the Phase 1 clinical trial; and CSP-9222 and OGX-225 are currently in pre-clinical development. More information about OncoGenex is available at www.oncogenex.com.


'/>"/>
SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. OncoGenex reports lead drug candidate OGX-011 achieved primary endpoint in Phase 2 Trial with second-line chemotherapy for prostate cancer
2. Sonus Pharmaceuticals and OncoGenex Technologies to Merge
3. OncoGenex to present at the Needham & Company 7th Annual Biotechnology & Medical Technology Conference
4. OncoGenex increases economic interest in lead cancer drug OGX-011
5. OncoGenex receives completed Special Protocol Assessment for primary registration study of lead drug candidate OGX-011
6. Sonus Pharmaceuticals and OncoGenex Technologies complete business combination; OncoGenex Pharmaceuticals to commence trading on NASDAQ Capital Market today
7. FDA Grants Fast Track Designation for OncoGenex Pharmaceuticals Lead Product Candidate OGX-011
8. OncoGenex Pharmaceuticals announces out-license of TOCOSOL Paclitaxel to Eagle Pharmaceuticals
9. OncoGenex To Present At The BioContact Quebec 2008 Annual Conference
10. OncoGenex Achieves Key Regulatory Milestone for Lead Product Candidate, OGX-011
11. OncoGenex Pharmaceuticals to Release Third Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2017)... ... September 19, 2017 , ... ... group of funded early-stage tech companies. “Grit” author Angela Duckworth and her team ... the ic@3401 community is Cooley, an international law firm with decades of experience ...
(Date:9/19/2017)... Washington, D.C. (PRWEB) , ... September 19, 2017 ... ... care during an biological outbreak is about to be eliminated, said Lyle Probst, ... makes ExcitePCR’s FireflyDX™ technologies different than other pathogen detection solutions, Probst ...
(Date:9/19/2017)... ... September 19, 2017 , ... ... a partnership with Cytena GmbH to launch the CloneSelect™ Single-Cell Printer™ in North ... to isolate single cells and provide visual documentation of monoclonality for use in ...
(Date:9/18/2017)... ... September 18, 2017 , ... Transportable ... biochar, briquettes, and torrefied wood is the topic of a September 27 ... the potential economic viability of transportable biomass conversion facilities for producing biochar, briquettes, ...
Breaking Biology Technology:
(Date:5/23/2017)... first robotic gym for the rehabilitation and functional motor sense evaluation of ... Italy . The first 30 robots will be available from June ... . The technology was developed and patented at the IIT laboratories and ... thanks to a 10 million euro investment from entrepreneur Sergio Dompè. ... ...
(Date:5/6/2017)... -- RAM Group , Singaporean based technology ... biometric authentication based on a novel  quantum-state ... perform biometric authentication. These new sensors are based on a ... Group and its partners. This sensor will have widespread ... security. Ram Group is a next generation sensor ...
(Date:4/18/2017)... April 18, 2017  Socionext Inc., a global expert in SoC-based ... edge server, the M820, which features the company,s hybrid codec technology. ... by Tera Probe, Inc., will be showcased during the upcoming Medtec ... show at the Las Vegas Convention Center ... Click here ...
Breaking Biology News(10 mins):